| Full Name | Jana M Hall |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 24 Years |
| Location | 320 E 2nd St, Libby, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063523629 | NPI | - | NPPES |
| 0063002 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 10356 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cabinet Peaks Medical Center | Libby, MT | Hospital |
| Libby Care Center | Libby, MT | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lincoln County Community Health Center Inc | 6507778537 | 13 |
News Archive
Children born with certain heart defects have impaired blood flow from the right ventricle to the pulmonary artery leading to the lungs, requiring implanted devices (known as right-ventricular outflow tract conduits) to maintain the flow. However, these conduits fail over time, and children typically face multiple open-heart operations during their lives to reopen the passage.
A frontline chemotherapy drug given to patients with pancreatic cancer is made less effective because similar compounds released by tumor-associated immune cells block the drug's action, research led by the University of Michigan Rogel Cancer Center found.
BioNeutral Group, Inc., a specialty life science technology-based company, today announced it is entering into discussions with the Kentucky Hospital Association (KHA) through its subsidiary Kentucky Hospital Services Corporation LLC (KHSC) to introduce BioNeutral's Ogiene™ and Ygiene™ products into its member hospital association.
New research has uncovered a precision medicine test using blood proteins to identify a novel patient subgroup of idiopathic multicentric Castleman disease (iMCD), a rare blood disorder, who are more likely to respond to siltuximab, the only FDA approved treatment for the disease.
› Verified 1 days ago
| Entity Name | Lincoln County Community Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477574713 PECOS PAC ID: 6507778537 Enrollment ID: O20040205001090 |
News Archive
Children born with certain heart defects have impaired blood flow from the right ventricle to the pulmonary artery leading to the lungs, requiring implanted devices (known as right-ventricular outflow tract conduits) to maintain the flow. However, these conduits fail over time, and children typically face multiple open-heart operations during their lives to reopen the passage.
A frontline chemotherapy drug given to patients with pancreatic cancer is made less effective because similar compounds released by tumor-associated immune cells block the drug's action, research led by the University of Michigan Rogel Cancer Center found.
BioNeutral Group, Inc., a specialty life science technology-based company, today announced it is entering into discussions with the Kentucky Hospital Association (KHA) through its subsidiary Kentucky Hospital Services Corporation LLC (KHSC) to introduce BioNeutral's Ogiene™ and Ygiene™ products into its member hospital association.
New research has uncovered a precision medicine test using blood proteins to identify a novel patient subgroup of idiopathic multicentric Castleman disease (iMCD), a rare blood disorder, who are more likely to respond to siltuximab, the only FDA approved treatment for the disease.
› Verified 1 days ago
| Entity Name | St Johns Lutheran Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952312050 PECOS PAC ID: 1557255676 Enrollment ID: O20040210000931 |
News Archive
Children born with certain heart defects have impaired blood flow from the right ventricle to the pulmonary artery leading to the lungs, requiring implanted devices (known as right-ventricular outflow tract conduits) to maintain the flow. However, these conduits fail over time, and children typically face multiple open-heart operations during their lives to reopen the passage.
A frontline chemotherapy drug given to patients with pancreatic cancer is made less effective because similar compounds released by tumor-associated immune cells block the drug's action, research led by the University of Michigan Rogel Cancer Center found.
BioNeutral Group, Inc., a specialty life science technology-based company, today announced it is entering into discussions with the Kentucky Hospital Association (KHA) through its subsidiary Kentucky Hospital Services Corporation LLC (KHSC) to introduce BioNeutral's Ogiene™ and Ygiene™ products into its member hospital association.
New research has uncovered a precision medicine test using blood proteins to identify a novel patient subgroup of idiopathic multicentric Castleman disease (iMCD), a rare blood disorder, who are more likely to respond to siltuximab, the only FDA approved treatment for the disease.
› Verified 1 days ago
| Entity Name | St Johns Lutheran Hospital Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1952312050 PECOS PAC ID: 1557255676 Enrollment ID: O20120405000136 |
News Archive
Children born with certain heart defects have impaired blood flow from the right ventricle to the pulmonary artery leading to the lungs, requiring implanted devices (known as right-ventricular outflow tract conduits) to maintain the flow. However, these conduits fail over time, and children typically face multiple open-heart operations during their lives to reopen the passage.
A frontline chemotherapy drug given to patients with pancreatic cancer is made less effective because similar compounds released by tumor-associated immune cells block the drug's action, research led by the University of Michigan Rogel Cancer Center found.
BioNeutral Group, Inc., a specialty life science technology-based company, today announced it is entering into discussions with the Kentucky Hospital Association (KHA) through its subsidiary Kentucky Hospital Services Corporation LLC (KHSC) to introduce BioNeutral's Ogiene™ and Ygiene™ products into its member hospital association.
New research has uncovered a precision medicine test using blood proteins to identify a novel patient subgroup of idiopathic multicentric Castleman disease (iMCD), a rare blood disorder, who are more likely to respond to siltuximab, the only FDA approved treatment for the disease.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jana M Hall, MD 320 E 2nd St, Libby, MT 59923-2010 Ph: (460) 283-6900 | Jana M Hall, MD 320 E 2nd St, Libby, MT 59923-2010 Ph: (406) 283-6900 |
News Archive
Children born with certain heart defects have impaired blood flow from the right ventricle to the pulmonary artery leading to the lungs, requiring implanted devices (known as right-ventricular outflow tract conduits) to maintain the flow. However, these conduits fail over time, and children typically face multiple open-heart operations during their lives to reopen the passage.
A frontline chemotherapy drug given to patients with pancreatic cancer is made less effective because similar compounds released by tumor-associated immune cells block the drug's action, research led by the University of Michigan Rogel Cancer Center found.
BioNeutral Group, Inc., a specialty life science technology-based company, today announced it is entering into discussions with the Kentucky Hospital Association (KHA) through its subsidiary Kentucky Hospital Services Corporation LLC (KHSC) to introduce BioNeutral's Ogiene™ and Ygiene™ products into its member hospital association.
New research has uncovered a precision medicine test using blood proteins to identify a novel patient subgroup of idiopathic multicentric Castleman disease (iMCD), a rare blood disorder, who are more likely to respond to siltuximab, the only FDA approved treatment for the disease.
› Verified 1 days ago
Daniel Williams, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 320 E 2nd St, Libby, MT 59923 Phone: 406-283-6919 | |
Clyde Allen Knecht, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 403 Utah Ave, Libby, MT 59923 Phone: 406-293-8321 Fax: 406-293-8584 | |
Dr. Mark S Heppe, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 214 E 3rd St, Libby, MT 59923 Phone: 406-293-9274 Fax: 406-293-9280 | |
Charles Brad Black, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 214 E 3rd St, Libby, MT 59923 Phone: 406-293-9274 Fax: 406-293-9280 | |
Dr. Jane Pauline Borish, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 350 Louisiana Ave, Libby, MT 59923 Phone: 406-293-0133 | |
Samantha Lynn Pyle, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 320 E 2nd St, Libby, MT 59923 Phone: 406-283-6900 Fax: 406-293-6622 |